Yes — a hepatitis B infection that looks "cleared" or sits quiet can come roaring back. This is called hepatitis B reactivation, and it usually happens when the immune system is suppressed (by chemotherapy, transplant drugs, or strong immune-modulating medicines). The virus that was being held in check starts replicating again, sometimes silently, sometimes with sudden liver damage.
treatable, not curable
testing, not symptoms, decides
| Item | Value |
|---|---|
| Curable? | managed — treatable, not curable |
| Tested by | exam + lab |
| Often | no symptoms |
| If you may have it | get tested — testing, not symptoms, decides |
What hepatitis B reactivation actually is
Hepatitis B is a vaccine-preventable liver infection caused by the hepatitis B virus (HBV) CDC, About HBV. After an acute infection — the short-term illness in the first six months after exposure — most adults clear the virus from their blood and develop protective antibodies. But "cleared" is misleading. HBV genetic material can linger inside liver cells for years even when standard blood tests turn negative for the surface antigen (HBsAg).
Reactivation is the loss of that immune control. A person who was HBsAg-negative with positive core antibody (a marker of past infection) can revert to HBsAg-positive, and someone with quiet chronic infection can see their viral load surge. It's almost always set off by something that blunts the immune response: cancer chemotherapy, rituximab and other B-cell-depleting drugs, high-dose steroids, anti-TNF agents used for inflammatory and autoimmune diseases and hepatitis, and organ-transplant immunosuppression. The deeper and longer the immune suppression, the higher the risk.
Symptoms — and the silent reality
Reactivation often gives no warning. Many people with chronic or reactivating HBV are asymptomatic, and the first sign may be an abnormal liver-enzyme result on a routine blood draw. When symptoms do appear, they mirror an acute flare: fatigue, fever, poor appetite, nausea, abdominal pain, dark urine, clay-colored stools, joint pain, and jaundice (yellowing of the skin and eyes from a backed-up liver).
Because the warning signs are easy to miss, reactivation is frequently caught late, after the liver is already inflamed. Guidelines lean on screening before immunosuppression rather than waiting for someone to feel sick. For a fuller breakdown of how an HBV flare presents, see our overview of hepatitis b symptoms.
How hepatitis B spreads in the first place
Reactivation is an old infection waking up, so how it spreads points back to how the person got HBV originally. HBV is blood-borne and sexually transmitted: it passes when blood, semen, or other body fluids from an infected person enter someone uninfected, through sex, shared needles or injection equipment, and from parent to baby at birth. It is not spread by sneezing, coughing, hugging, sharing utensils, or through food and water.
On average, symptoms of a new acute infection appear about 90 days after exposure, with a range of roughly 60 to 150 days. If you're unsure when an exposure happened, our guide on when to test after exposure explains the testing windows that matter.
How reactivation is tested for
Diagnosis rests on a triple serologic panel: HBsAg (marks active infection), anti-HBs (immunity or recovery), and total anti-HBc (past or current infection) CDC, HBV testing. The core antibody is the key player for reactivation risk. A positive total anti-HBc, even with negative HBsAg, flags someone who was infected before and can reactivate under immunosuppression.
The CDC now recommends screening all adults aged 18 and older at least once in their lifetime, and pregnant people during each pregnancy CDC, 2023. Before starting any meaningfully immunosuppressive therapy, clinicians should run this panel and, when markers are positive, add an HBV DNA viral load to set a baseline. Monitoring HBV DNA and liver enzymes during and after treatment catches reactivation early.
Testing is a standard blood draw, with results usually back in a few days. You don't have to wait for an appointment with a liver specialist to start: many people get tested through health departments, Planned Parenthood, and Title X clinics at free or low cost, and you can compare testing providers if you'd rather order it yourself.
Treatment and prevention of reactivation
Acute hepatitis B usually needs only supportive care, because most adults clear it on their own. Chronic HBV has no cure, but FDA-approved antivirals can suppress the virus and protect the liver, and these same drugs are the cornerstone of reactivation prevention.
The standard approach is prophylactic antiviral therapy: starting tenofovir or entecavir in people at risk before immunosuppression begins, rather than reacting after the liver is hit AASLD, 2018. These medicines suppress replication and cut long-term liver-cancer risk, but they control rather than cure. Clearance happens in only about 2–5% of people even after a decade of treatment, so most take them for the full duration of immunosuppression and often a defined stretch beyond it.
A common mistake is stopping early once you feel fine; abrupt withdrawal can itself provoke a flare, so the stop is timed and monitored by a specialist. For the full picture of regimens and monitoring, see hepatitis b treatment.
| Scenario | HBV markers | Typical management before immunosuppression |
|---|---|---|
| Active chronic infection | HBsAg positive | Antiviral therapy plus close HBV DNA and liver-enzyme monitoring |
| Past/resolved infection | HBsAg negative, anti-HBc positive | Prophylactic antiviral or scheduled monitoring, depending on how immunosuppressive the drug is |
| Vaccinated, never infected | Anti-HBs positive, anti-HBc negative | No HBV-specific treatment needed |
Complications if reactivation is missed
Untreated, an HBV flare during immunosuppression can be severe, far worse than an ordinary acute infection, because the immune rebound that follows can damage the liver quickly. Over time, untreated chronic hepatitis B can cause:
- Liver damage and ongoing inflammation that scars the organ over years.
- Cirrhosis — extensive scarring that stiffens the liver and impairs its ability to filter blood and make proteins.
- Hepatocellular carcinoma (primary liver cancer), a risk that rises with chronic, uncontrolled infection.
- Liver failure and death in the most severe flares, which is why reactivation is treated as a preventable emergency rather than a wait-and-see problem.
Reactivation gets such serious attention because of timing: in a person on chemotherapy, a missed flare can interrupt life-saving cancer treatment or trigger acute liver failure before anyone realizes the virus woke up.
How to prevent it
Vaccination is the best primary prevention. ACIP recommends the hepatitis B vaccine for all adults aged 19–59, and for adults 60 and older who have risk factors CDC, 2022. After exposure to an HBsAg-positive source, post-exposure prophylaxis is hepatitis B immune globulin (HBIG) plus the vaccine, given as soon as possible — ideally within 24 hours.
For reactivation specifically, prevention is two steps: screen everyone before starting immunosuppressive therapy, and start antiviral prophylaxis in anyone with HBV markers when the drug carries real reactivation risk. Beyond the clinic, condoms used every time lower the risk of acquiring HBV sexually, and routine testing catches the infections that have no symptoms, which is most of them.
When to see a clinician
See a clinician before you start chemotherapy, a transplant, rituximab, anti-TNF therapy, or long-term steroids, and ask specifically whether you've been screened for hepatitis B. If you know you've had HBV in the past, tell every prescriber, because the core antibody can persist even when the virus seems gone. If you develop new fatigue, jaundice, dark urine, or abdominal pain while on immunosuppressive treatment, get liver enzymes and HBV DNA checked promptly. Clinics handle this daily.